<DOC>
	<DOCNO>NCT00299182</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose AMG 531 give treat thrombocytopenia ( low platelet count ) patient receive chemotherapy . Researchers also look safety effectiveness AMG 531 . Primary Objectives : 1 . To determine clinical safety tolerability AMG 531 administer follow chemotherapy ( R-HyperCVAD alternate R-Ara-C/MTX ) patient non-Hodgkin 's lymphoma . 2 . To determine optimal biologic dose ( OBD ) AMG 531 patient receive R-HyperCVAD R-Ara-C/MTX . 3 . To evaluate effect AMG 531 degree duration thrombocytopenia platelet recovery follow chemotherapy ( chemo ) . Secondary Objectives : 1 . To evaluate limited pharmacokinetics AMG 531 administer S.C. route chemotherapy .</brief_summary>
	<brief_title>Study AMG 531 Evaluate Safety &amp; Efficacy Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Platelets cell help make blood clot . A decrease platelets cause bleeding , may prevent delay patient receive chemotherapy . R-HyperCVAD ( rituximab , cyclophosphamide , vincristine , doxorubicin , dexamethasone ) R-Ara-C/MTX ( rituximab , cytarabine , methotrexate ) two chemotherapy regimen know increase risk lower platelet count . Researchers want find AMG 531 low risk severity side effect . AMG 531 protein stimulates platelet production . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You complete medical history physical exam , include measurement vital sign ( temperature , pulse , breathe rate , blood pressure ) . You blood collect ( 3 teaspoon ) routine test . Radiologic test CT MRI scan do need . Women able child must negative blood pregnancy test . You also 1 teaspoon blood drawn see antibody study drug . If find eligible take part study , randomly assign ( toss coin ) one four treatment group . These 4 group also split 2 separate subgroup ( Arm A Arm B ) . Participants Arm A either receive AMG 531 placebo Day -5 ( 5 day chemotherapy start ) Day 5 ( 5 day chemotherapy start ) . A placebo substance look like study drug active ingredient . Every 2 3 participant Arm A receive AMG 531 . One every 3 participant Arm A receive placebo . Participants Arm B receive either AMG 531 placebo Day 5 7 . Every 2 3 participant Arm B receive AMG 531 . One every 3 participant Arm B receive placebo . The dose AMG 531 participant Arms A B receive depend enroll study . There 3 different dose level AMG 531 study . Each new group participant receive high dose previous group . All participant receive treatment R-HyperCVAD R-Ara-C/MTX chemotherapy vein alternate cycle . In Cycle 1 , participant receive R-HyperCVAD . Each cycle 3 week long . Three ( 3 ) week later , Cycle 2 , participant receive either AMG 531 placebo follow R-Ara-C/MTX . The AMG 531/placebo give injection skin Days -5 5 ( Arm A ) Days 5 7 ( Arm B ) . After 2 cycle treatment , base response disease tolerance treatment , participant may able receive 4 cycle chemotherapy follow AMG 531 . For Cycles 3-6 , follow schedule therapy first 2 cycle . The dose AMG 531 may increase one time point study base response platelet count . Blood ( 1 teaspoon ) collect evaluation anti-AMG 531 antibody status end Cycles 2 4 . You take study disease get bad intolerable side effect occur . The number blood test draw depend clinical condition . These sample ( 1 teaspoon ) take least 2 time week often day anticipate period low blood cell count . At end study , interim medical history physical exam , include measurement vital sign . You blood ( 1 teaspoon ) drawn routine end-of-study analysis . Blood ( 1 teaspoon ) also collect evaluation anti-AMG 531 antibody status . This investigational study . R-HyperCVAD R-Ara-C/MTX commercially available chemotherapy drug . AMG 531 FDA approve commercially available . At time , AMG 531 use study research purpose . About 36 evaluable patient ( maximum 50 patient ) take part study . All enrol University Texas ( UT ) M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients diagnosis previously untreated aggressive nonHodgkin 's lymphoma , include patient mantle cell lymphoma , receive treatment RHyperCVAD RAraC/MTX . Patients Rituximab use , due contraindication , eligible . Patients whose therapy switch ( R ) HyperCVAD initial treatment ( R ) CHOP , aggressive disease also eligible study . 2 . Patients age &gt; /= 18 year . 3 . Karnofsky Performance Scale &gt; /= 70 . 4 . Adequate hematologic ( ANC &gt; /= 1000/mm ( 3 ) , platelet count &gt; /= 100,000/mm ( 3 ) Hgb &gt; /= 8gm/dL ) , renal ( serum creatinine &lt; 2mg/dL ) , hepatic function ( total bilirubin &lt; /= 2 time , serum glutamate pyruvate transaminase ( SGPT ) serum glutamate oxaloacetate transaminase ( SGOT ) &lt; /= 3 time upper limit respective normal range ) . 5 . Patients ( male female ) childbearing potential ( define postmenopausal 12 month previous surgical sterilization ) must use adequate birth control . 6 . Institutional Review Board ( IRB ) approve sign informed consent . 1 . Pregnant lactating woman . 2 . History Central Nervous System ( CNS ) involvement . 3 . Comorbid medical psychiatric illness preclude treatment intense dose chemotherapy . 4 . Patients history deep vein thrombosis ( DVT ) pulmonary embolus . 5 . History platelet disorder include Idiopathic thrombocytopenic purpura ( ITP ) , Thrombotic thrombocytopenic purpura ( TTP ) bleed disorder . 6 . Prior surgery Radiation Therapy ( RT ) within 2 week study entry . 7 . Patients significant cardiac disease ( New York Heart Association ( NYHA ) Class III IV ) , dysrrhythmia , recent history myocardial ischemia ( MI ) ischemia , transient ischemic attack cerebrovascular accident ( CVA ) within previous 6 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>AMG 531</keyword>
	<keyword>Romiplostim</keyword>
	<keyword>Placebo</keyword>
	<keyword>R-HyperCVAD</keyword>
	<keyword>R-Ara-C/MTX</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Decadron</keyword>
	<keyword>Neosar</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrocholoride</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
</DOC>